Tarsus Pharmaceuticals (TARS) Insider Yarno Buys 2,954 Shares

Wendy Yarno Expands Holdings in Tarsus Pharmaceuticals

Wendy Yarno purchased 2,954 shares of Tarsus Pharmaceuticals, Inc. (NasdaqGS: TARS) on June 12, 2026, according to recent disclosures filed with the Securities and Exchange Commission. The acquisition places additional focus on the scale of recent executive transactions at the biotechnology firm, where several insiders have adjusted their personal holdings over the summer months.

Busy Stretch of Insider Transactions at Tarsus

The mid-June reporting period brought a flurry of activity across the company roster. On June 12, 2026, Andrew Goldberg and William Link both acquired 2,954 shares, while Scott Morrison parted with 2,954 shares. Shortly after, Katherine Goodrich sold 2,954 shares on June 15, 2026, at an average price of $62.08 for a total value of $183,384.32. Andrew Goldberg returned to the transaction records on June 25, 2026, picking up another 2,417 shares.

Tarsus Stock Performance and Valuation Context

Tarsus shares recently changed hands around $61.85, sitting inside a 52-week trading window spanning from $53.89 to $91.53. The firm carries a market capitalization of roughly $3.62 billion and a forward P/E ratio of 32.06. Profitability metrics show a negative net margin of 7.7% and a return on equity of negative 13.7% over the trailing period, alongside annual revenue of $606.33 million reflecting a 69.4% growth rate.

Wall Street Analyst Views and Price Targets

Coverage from major financial institutions shows steady optimism regarding the biotechnology firm's commercial progress. On July 9, 2026, HC Wainwright & Co. reiterated its Buy rating and an $88.00 price target. Guggenheim kept a Buy rating on July 21, 2026, with an 89.00 target. Mizuho maintained an Outperform rating on July 31, 2026, pointing to a $98.00 target. Oppenheimer followed on August 12, 2026, keeping an Outperform rating while lifting its target to $100.00. Jefferies later maintained a Buy rating on September 8, 2026, raising its target to $105.00. The broader consensus lists nine analyst opinions yielding a strong buy recommendation and a mean price target of $97.67.

Behind the Business at Tarsus

Tarsus Pharmaceuticals, Inc. focuses on developing and commercializing therapeutic treatments for eye care, led by its flagship product XDEMVY for demodex blepharitis. The company also advances clinical candidates targeting ocular rosacea and the prevention of Lyme disease. These ongoing commercial efforts and clinical pipeline updates continue to draw attention from both market analysts and corporate insiders.

Looking Ahead to Autumn Reporting

Market participants will monitor further insider filings and upcoming corporate updates as the company approaches its next quarterly financial report, scheduled for November 4, 2026. Insider transaction reports offer a window into how leadership views personal commitments to the business, though these filings reflect past decisions rather than current price guarantees.